Concepts (83)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proteogenomics | 4 | 2023 | 69 | 0.620 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2024 | 225 | 0.510 |
Why?
|
| Endoribonucleases | 2 | 2024 | 83 | 0.440 |
Why?
|
| RNA, Double-Stranded | 2 | 2024 | 63 | 0.280 |
Why?
|
| Pyroptosis | 1 | 2024 | 20 | 0.240 |
Why?
|
| Taxoids | 1 | 2024 | 67 | 0.240 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2023 | 18 | 0.220 |
Why?
|
| Proteostasis | 1 | 2023 | 34 | 0.210 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2023 | 144 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 156 | 0.210 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 303 | 0.200 |
Why?
|
| Thiazoles | 1 | 2023 | 96 | 0.200 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 353 | 0.190 |
Why?
|
| Spliceosomes | 1 | 2021 | 48 | 0.180 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 580 | 0.180 |
Why?
|
| Immunity | 1 | 2021 | 183 | 0.170 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 2478 | 0.170 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 290 | 0.170 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 101 | 0.170 |
Why?
|
| Neoplasms | 2 | 2024 | 2697 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 714 | 0.160 |
Why?
|
| Carcinogenesis | 1 | 2020 | 335 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 258 | 0.140 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 1672 | 0.110 |
Why?
|
| Proteomics | 2 | 2022 | 475 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 519 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2021 | 655 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 3297 | 0.060 |
Why?
|
| Bridged-Ring Compounds | 1 | 2024 | 16 | 0.060 |
Why?
|
| Female | 7 | 2024 | 64573 | 0.060 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2024 | 122 | 0.060 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 99 | 0.060 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2024 | 112 | 0.060 |
Why?
|
| Germ Cells | 1 | 2024 | 185 | 0.050 |
Why?
|
| NFI Transcription Factors | 1 | 2023 | 50 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 83 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2023 | 42 | 0.050 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2023 | 38 | 0.050 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 19 | 0.050 |
Why?
|
| Inflammasomes | 1 | 2024 | 149 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2023 | 74 | 0.050 |
Why?
|
| Carboplatin | 1 | 2022 | 78 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2023 | 215 | 0.050 |
Why?
|
| Mice | 3 | 2024 | 17624 | 0.050 |
Why?
|
| APOBEC Deaminases | 1 | 2020 | 6 | 0.050 |
Why?
|
| Humans | 8 | 2024 | 121793 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 320 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 76 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2021 | 228 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 88 | 0.040 |
Why?
|
| Introns | 1 | 2021 | 301 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2021 | 290 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 6275 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2023 | 788 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 187 | 0.040 |
Why?
|
| RNA Splicing | 1 | 2021 | 223 | 0.040 |
Why?
|
| Exome | 1 | 2024 | 1034 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2020 | 354 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2021 | 281 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2020 | 330 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 388 | 0.040 |
Why?
|
| Animals | 3 | 2024 | 33870 | 0.040 |
Why?
|
| DNA Damage | 1 | 2020 | 517 | 0.040 |
Why?
|
| DNA Repair | 1 | 2020 | 580 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 496 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 535 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2023 | 2829 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2020 | 1616 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3431 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1242 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 2997 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1791 | 0.030 |
Why?
|
| Aged | 2 | 2021 | 18732 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 4623 | 0.020 |
Why?
|
| Middle Aged | 2 | 2021 | 25516 | 0.020 |
Why?
|
| Adult | 2 | 2021 | 28549 | 0.020 |
Why?
|
| Infant | 1 | 2024 | 12177 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2024 | 13661 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2021 | 4518 | 0.020 |
Why?
|
| Male | 2 | 2024 | 59243 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 8676 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 18773 | 0.020 |
Why?
|
| Child | 1 | 2024 | 23789 | 0.010 |
Why?
|